A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
← catalyst calendarNCT06469281 · readout in 1,377 d
Sponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
90estimated
Sites
5
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-08-06 | actual | When the study began enrolling |
| Primary completion | 2030-05-27 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-05-27 | estimated | The whole study's end, after follow-up |
| First posted | 2024-06-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Epithelial Ovarian Cancer
- Primary Peritoneal Carcinoma
- Fallopian Tube Cancer
Interventions
- Other: 27T51
- Drug: Cemiplimab — also filed as Libtayo, REGN2810
- Drug: Bevacizumab — also filed as Avastin, Mvasi, Vegzelma, Zirabe
Primary outcomes
what the primary-completion date above is the date OFIncidence of treatment emergent adverse events (TEAEs)
measured Up to 18 months
Incidence of adverse events of special interest (AESIs)
measured Up to 18 months
Incidence of adverse events of dose limiting toxicities (DLTs)
measured Up to 18 months
Manufacturing feasibility of 27T51
measured Up to 3 years
Overall response rate (ORR) as assessed by the investigator
measured Up to 48 months
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed